Research map: Hyperuricemia and prevention of cardiometabolic disease: Unexplored is not unexpected

Back to the article

Papers in this map

  1. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout · William B. White · 2018 · 921 citations · Cited by this paper
  2. Timely allopurinol in asymptomatic hyperuricemia: modelling a hypothesis worth prospective investigation. Authors’ reply · András Inotai · 2026 · Cites this paper
  3. Early vasopressin in septic shock: Which evidence should we trust? · 2026 · Related
  4. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes · Alessandro Doria · 2020 · 392 citations · Cited by this paper
  5. Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS/LABA/LAMA therapies in obstructive airway diseases · 2026 · Related
  6. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial · Isla S. Mackenzie · 2020 · 359 citations · Cited by this paper
  7. Clarifying the lipid signal: non-HDL cholesterol, remnant cholesterol and metabolic risk in primary care · 2026 · Related
  8. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years · Agostino Virdis · 2019 · 283 citations · Cited by this paper
  9. Left atrial enlargement without atrial fibrillation: a warning signal rather than a treatment target · 2026 · Related
  10. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia · Roger Scott Blumenthal · 2026 · 232 citations · Cited by this paper
  11. Rethinking residual sex effects in frailty-adjusted ICU mortality · 2026 · Related
  12. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial · Isla S. Mackenzie · 2022 · 168 citations · Cited by this paper
  13. Cardiac rehabilitation referral and access by country income class: Comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s 2025 Global Audit Update · 2026 · Related
  14. Medication adherence in hypertension · Neil R Poulter · 2019 · 166 citations · Cited by this paper
  15. Beyond comorbidities: Age as an independent predictor of survival in pulmonary arterial hypertension · 2026 · Related
  16. Update in uric acid, hypertension, and cardiovascular diseases · Masanari Kuwabara · 2023 · 93 citations · Cited by this paper
  17. Clinical and prognostic significance of urinary albumin-to-creatinine ratio in heart failure: insights from the RICA-2 registry · 2026 · Related
  18. Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome · Masanari Kuwabara · 2024 · 8 citations · Cited by this paper
  19. Allopurinol Adherence in US Patients With Gout · Kevin R. Riggs · 2024 · 7 citations · Cited by this paper
  20. Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study · Antonio Ruiz‐García · 2024 · 4 citations · Cited by this paper
  21. Unlocking the benefits of allopurinol: the role of timely initiation and adherence in cardiovascular and renal outcomes in hyperuricemia · András Inotai · 2026 · 3 citations · Cited by this paper
  22. Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study · Joseph Magagnoli · 2025 · 2 citations · Cited by this paper
  23. Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation · Claudio Borghi · 2026 · 2 citations · Cited by this paper
  24. Management and long-term serum urate control in gout: a population-based primary care cohort study · Maria Antònia Pou · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)